In vitro investigation of elevated hemolysis susceptibility in neonatal blood
IntroductionHemolysis is a relevant complication and is responsible for morbidity and mortality of neonatal extracorporeal membrane oxygenation (ECMO) therapy. For novel therapies like artificial placenta, hemolysis could also lead to complications or therapy failure, especially since the targeted p...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2025.1616084/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222420624310272 |
|---|---|
| author | Jan Heyer Stella Volmering Camila Hoyos-Banchon Sarah Koc Lydia Jeremiah Ulrich Steinseifer Thorsten Orlikowsky Sebastian V. Jansen Johanna C. Clauser Mark Schoberer |
| author_facet | Jan Heyer Stella Volmering Camila Hoyos-Banchon Sarah Koc Lydia Jeremiah Ulrich Steinseifer Thorsten Orlikowsky Sebastian V. Jansen Johanna C. Clauser Mark Schoberer |
| author_sort | Jan Heyer |
| collection | DOAJ |
| description | IntroductionHemolysis is a relevant complication and is responsible for morbidity and mortality of neonatal extracorporeal membrane oxygenation (ECMO) therapy. For novel therapies like artificial placenta, hemolysis could also lead to complications or therapy failure, especially since the targeted patients are born at the borderline of viability. Standardized in vitro blood testing using animal blood is commonly used to assess the hemolytic potential of newly developed systems during their design and development. However, neonatal human blood differs from animal blood. For example, neonatal blood exhibits a higher erythrocyte volume, lower overall viscosity, and greater erythrocyte elasticity. This study investigates whether the porcine blood analog, commonly used in standardized protocols, can also be used to assess hemolysis in neonatal blood.MethodsHuman neonatal blood was harvested from placentas and umbilical cords of neonates born by cesarean section. Porcine blood was obtained from a local abattoir. Both collection processes followed predefined standardized protocols. Normalized Index for hemolysis (NIH) was calculated based on determined free plasma hemoglobin.ResultThere was a significantly (p < 0.05) higher normalized index of hemolysis in the human neonatal blood group (NIH=0.165 g 100 L−1; SD=0.082) compared to the porcine group (NIH=0.101 g 100l−1; SD=0.038). In contrast, under static reference conditions, neonatal blood exhibited lower hemolysis (NIH=0.025 g 100 L−1; SD=0.018) than porcine blood (NIH=0.055 g 100l−1; SD=0.038).DiscussionIn standardized in vitro hemolysis testing, porcine blood might not serve as a suitable analog for human neonatal blood, as it significantly underestimates the hemolysis potential observed in neonatal blood. |
| format | Article |
| id | doaj-art-c1da20fe3c4447e2a977dee9e5b4a4f8 |
| institution | Kabale University |
| issn | 2296-2360 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj-art-c1da20fe3c4447e2a977dee9e5b4a4f82025-08-26T05:28:10ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-08-011310.3389/fped.2025.16160841616084In vitro investigation of elevated hemolysis susceptibility in neonatal bloodJan Heyer0Stella Volmering1Camila Hoyos-Banchon2Sarah Koc3Lydia Jeremiah4Ulrich Steinseifer5Thorsten Orlikowsky6Sebastian V. Jansen7Johanna C. Clauser8Mark Schoberer9Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, GermanyDepartment of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, GermanyDepartment of Pediatric and Adolescent Medicine, Neonatology, Medical Faculty, University Hospital RWTH Aachen, Aachen, GermanyDepartment of Pediatric and Adolescent Medicine, Neonatology, Medical Faculty, University Hospital RWTH Aachen, Aachen, GermanyDepartment of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, GermanyDepartment of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, GermanyDepartment of Pediatric and Adolescent Medicine, Neonatology, Medical Faculty, University Hospital RWTH Aachen, Aachen, GermanyDepartment of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, GermanyDepartment of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, GermanyDepartment of Pediatric and Adolescent Medicine, Neonatology, Medical Faculty, University Hospital RWTH Aachen, Aachen, GermanyIntroductionHemolysis is a relevant complication and is responsible for morbidity and mortality of neonatal extracorporeal membrane oxygenation (ECMO) therapy. For novel therapies like artificial placenta, hemolysis could also lead to complications or therapy failure, especially since the targeted patients are born at the borderline of viability. Standardized in vitro blood testing using animal blood is commonly used to assess the hemolytic potential of newly developed systems during their design and development. However, neonatal human blood differs from animal blood. For example, neonatal blood exhibits a higher erythrocyte volume, lower overall viscosity, and greater erythrocyte elasticity. This study investigates whether the porcine blood analog, commonly used in standardized protocols, can also be used to assess hemolysis in neonatal blood.MethodsHuman neonatal blood was harvested from placentas and umbilical cords of neonates born by cesarean section. Porcine blood was obtained from a local abattoir. Both collection processes followed predefined standardized protocols. Normalized Index for hemolysis (NIH) was calculated based on determined free plasma hemoglobin.ResultThere was a significantly (p < 0.05) higher normalized index of hemolysis in the human neonatal blood group (NIH=0.165 g 100 L−1; SD=0.082) compared to the porcine group (NIH=0.101 g 100l−1; SD=0.038). In contrast, under static reference conditions, neonatal blood exhibited lower hemolysis (NIH=0.025 g 100 L−1; SD=0.018) than porcine blood (NIH=0.055 g 100l−1; SD=0.038).DiscussionIn standardized in vitro hemolysis testing, porcine blood might not serve as a suitable analog for human neonatal blood, as it significantly underestimates the hemolysis potential observed in neonatal blood.https://www.frontiersin.org/articles/10.3389/fped.2025.1616084/fullpreterm infantsartificial placentaneonatal blood hemolysisneonatal ECMOporcine vs. neonatal blood |
| spellingShingle | Jan Heyer Stella Volmering Camila Hoyos-Banchon Sarah Koc Lydia Jeremiah Ulrich Steinseifer Thorsten Orlikowsky Sebastian V. Jansen Johanna C. Clauser Mark Schoberer In vitro investigation of elevated hemolysis susceptibility in neonatal blood Frontiers in Pediatrics preterm infants artificial placenta neonatal blood hemolysis neonatal ECMO porcine vs. neonatal blood |
| title | In vitro investigation of elevated hemolysis susceptibility in neonatal blood |
| title_full | In vitro investigation of elevated hemolysis susceptibility in neonatal blood |
| title_fullStr | In vitro investigation of elevated hemolysis susceptibility in neonatal blood |
| title_full_unstemmed | In vitro investigation of elevated hemolysis susceptibility in neonatal blood |
| title_short | In vitro investigation of elevated hemolysis susceptibility in neonatal blood |
| title_sort | in vitro investigation of elevated hemolysis susceptibility in neonatal blood |
| topic | preterm infants artificial placenta neonatal blood hemolysis neonatal ECMO porcine vs. neonatal blood |
| url | https://www.frontiersin.org/articles/10.3389/fped.2025.1616084/full |
| work_keys_str_mv | AT janheyer invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood AT stellavolmering invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood AT camilahoyosbanchon invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood AT sarahkoc invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood AT lydiajeremiah invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood AT ulrichsteinseifer invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood AT thorstenorlikowsky invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood AT sebastianvjansen invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood AT johannacclauser invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood AT markschoberer invitroinvestigationofelevatedhemolysissusceptibilityinneonatalblood |